Condition: Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Journal: The Lancet. Oncology
Treatment Used: First-Line Pembrolizumab vs. Chemotherapy
Number of Patients: 307
Published: April 04, 2021
Summary: Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.